Dermal Fillers: A Clinical Guide for UK Practitioners

Understanding Hyaluronic Acid as a Dermal Filler Substrate

The vast majority of injectable dermal fillers used in contemporary UK aesthetic practice are based on hyaluronic acid (HA), a naturally occurring glycosaminoglycan found in the extracellular matrix of human connective tissue. Endogenous HA is rapidly degraded by hyaluronidase, with a half-life measured in hours to days in its unmodified form. Commercial dermal fillers stabilise HA through a chemical process called cross-linking, which extends the product's residence time in tissue from weeks to many months.

Cross-linking is achieved predominantly via BDDE (1,4-butanediol diglycidyl ether), a bifunctional epoxide that forms covalent bonds between HA chains. The degree and pattern of cross-linking directly determines the rheological properties of the finished gel, which in turn governs its clinical suitability for different anatomical areas. Practitioners who understand this chemistry are better placed to match product to indication and to communicate material choices to patients.

Rheological Parameters: G-Prime and Viscosity

Two rheological metrics dominate product-to-indication matching in clinical literature: elastic modulus (G-prime) and viscosity. G-prime (G') represents the storage modulus of a viscoelastic gel and is a measure of its stiffness and resistance to deformation under stress. A high G-prime product holds its shape under compression, making it appropriate for structural support in areas such as the jawline or chin. A low G-prime product flows under stress and integrates more readily into soft tissue, which suits delicate areas such as the periocular zone and lips.

Viscosity describes the resistance of the gel to flow and is directly relevant to injectability. High-viscosity gels require greater injection pressure, which influences syringe and needle selection. Some manufacturers use a monophasic gel architecture (a single cross-linked network), whilst others produce biphasic gels (cross-linked particles suspended in a carrier). These structural differences affect how the product disperses in tissue and how it responds to digital moulding post-injection.

Published rheological data vary by method and temperature of measurement; practitioners should review manufacturer-supplied data in context and not rely on single-parameter comparisons. Peer-reviewed comparisons, including those published in the Journal of Cosmetic Dermatology and Dermatologic Surgery, provide independent benchmarks for commonly used brands.

Brand Families and Their Rheological Profiles

The UK market supports a range of established brand families, each with a distinct manufacturing approach and portfolio of products calibrated to different treatment areas. The following overview is intended as a clinical orientation only; practitioners must consult the current Summary of Product Characteristics (SPC) for each specific product before clinical use.

Restylane (Galderma): A biphasic, BDDE-cross-linked range including Restylane Lyft, Restylane Defyne, Restylane Refyne, Restylane Kysse, and Restylane Volyme, among others. Published clinical trial data for several lines extend to 12 months or beyond (Galderma SPC; see also peer-reviewed publications in Aesthetic Surgery Journal).
Juvederm (Allergan Aesthetics): A monophasic, Vycross or Hylacross cross-linked portfolio including Juvederm Voluma, Volift, Volbella, Vollure, and Ultra ranges. Vycross technology combines differing molecular weights of HA to achieve high cross-linking efficiency with a lower BDDE residual (Allergan SPC).
Stylage (Vivacy Laboratories): A French-manufactured range using IPN-like technology and incorporating the antioxidant mannitol to reduce free-radical degradation in tissue. The portfolio spans Stylage S, M, L, XL, and Special Lips (Vivacy SPC).
Belotero (Merz Aesthetics): Uses Cohesive Polydensified Matrix (CPM) technology, producing a product with heterogeneous cross-link density designed to integrate into tissue with minimal Tyndall effect, particularly in superficial skin planes (Merz SPC).
Teosyal (Teoxane): A Swiss-manufactured range using RHA (Resilient Hyaluronic Acid) technology in its dynamic lines, intended to mimic the mechanical behaviour of endogenous HA. The portfolio includes Teosyal PureSense, RHA 1-4, and Ultimate (Teoxane SPC).
Revolax (Across Co.): A Korean-manufactured monophasic gel range offering Fine, Deep, and Sub-Q grades. Widely used in the UK owing to its accessible price point and consistent quality; clinical validation data are more limited than European brands.
Regenovue (Hugel): Another Korean-origin range using SHAPE technology; Fine, Deep, Deep Plus, and Sub-Q grades. MHRA registration as a Class III medical device is a minimum supply requirement for any product placed on the UK market.

Browse the full dermal filler range available through Longeva Aesthetics at /collections/all-products, including options from several of the brand families listed above.

Indications and Area-Based Product Selection

Dermal filler indications in licensed aesthetic practice span a broad range of facial zones. The following categorisation reflects general clinical consensus; individual patient anatomy and practitioner training always take precedence.

Volume restoration (mid-face, cheeks, temples): Higher G-prime, higher viscosity products. Injected deep to the subcutaneous fat compartments or supraperiosteal. Indicated for age-related volume loss, as documented in the literature on facial ageing (Rohrich and Pessa, Plastic and Reconstructive Surgery, 2007).
Structural definition (jawline, chin, nose): High G-prime products capable of withstanding compressive forces from overlying muscle and skin. Precision of placement is critical given proximity to named vessels.
Lip augmentation and definition: Low to moderate G-prime, highly flexible products. Lip mucosa is heavily vascularised; aspiration technique and slow injection are standard clinical practice.
Perioral lines and marionette lines: Superficial to intermediate-depth placement with low to moderate viscosity products. Overfilling in this area carries a risk of unnatural appearance.
Tear trough (periocular): Low G-prime products with low Tyndall risk. A technically advanced area; national guidelines from the British College of Aesthetic Medicine (BCAM) and the Joint Council for Cosmetic Practitioners (JCCP) recommend this area be reserved for practitioners with advanced training credentials.
Dorsal hand rejuvenation: High-volume, high-viscosity products. Cannula technique is preferred to reduce haematoma risk.

Regulatory Status: MHRA Class III Medical Device

Following the UK Medicines and Healthcare products Regulatory Agency's post-Brexit reclassification, all injectable HA dermal fillers are classified as Class III medical devices under the UK Medical Devices Regulations 2002 (as amended). Class III represents the highest risk category for medical devices, requiring conformity assessment by a UK Approved Body (or a recognised international equivalent under mutual recognition) and listing on the MHRA Device Registration system.

Practitioners should verify that any product they source bears a valid UK CA mark (or remains on the MHRA's transitional arrangements register), and that their supplier can produce device registration evidence on request. Products that do not carry the necessary regulatory authorisation must not be used clinically. Longeva Aesthetics supplies only MHRA-registered products; practitioners can request regulatory documentation for any line through the account portal.

Practitioners in England who perform cosmetic procedures including injectable dermal fillers are required to hold a licence issued by the Care Quality Commission (CQC) since the enactment of the Health and Care Act 2022. The JCCP maintains a public register of practitioners who have demonstrated appropriate training and qualification, and the JCCP register is cited by NHS England as a reference standard for safe practice.

Contraindications

Contraindications for HA dermal fillers are documented in each product SPC and should be reviewed for every product and every patient. Across the major product families, the following contraindications appear consistently.

Known hypersensitivity to HA or to BDDE residuals.
Active infection, inflammation, or skin condition at or near the intended injection site, including active acne vulgaris, herpes simplex, or impetigo.
Pregnancy and breastfeeding (insufficient safety data; manufacturer SPCs universally list this as a contraindication).
Autoimmune disorders or conditions requiring long-term immunosuppressive therapy (relative contraindication; assess individually and consult current BCAM guidance).
Coagulopathies or current anticoagulant therapy (increased bruising and haematoma risk; aspirin and NSAIDs should be reviewed pre-procedure with GP awareness where clinically relevant).
Previous permanent filler in the proposed treatment area (risk of granuloma and complex vascular anatomy).
Keloid or hypertrophic scarring tendency (relative contraindication).

The JCCP and BCAM both produce clinical guidance documents covering contraindication assessment and the use of pre-treatment consent protocols. These should form part of every practitioner's standard operating procedure.

Storage, Handling, and Cold Chain

HA dermal fillers are biological-origin products and require careful handling to preserve their rheological integrity and sterility. The majority of manufacturer SPCs specify storage at 2 to 25 degrees Celsius, away from direct sunlight and freezing. Products should not be used if there is any evidence of damage to the sterile packaging, discolouration, or cloudiness in the syringe.

Fillers should be allowed to reach room temperature before injection; cold gel has a higher viscosity and requires greater injection pressure, increasing the risk of backflow and vessel trauma. Lidocaine-containing formulations (pre-mixed products) should be handled with the same aseptic technique as any injectable. Once the sterile seal is broken, the product must be used immediately and any remainder discarded; sharing between patients is prohibited under the manufacturer SPC and UK infection control standards.

View the full range of dermal fillers with verified cold-chain supply at /collections/dermal-fillers.

Hyaluronidase and Vascular Occlusion Management

Every practitioner who injects HA dermal fillers must have immediate access to hyaluronidase (Hyalase, as licensed in the UK) and must be trained in the recognition and emergency management of vascular occlusion. The British Association of Aesthetic Plastic Surgeons (BAAPS), BCAM, and the JCCP all mandate that practitioners hold an appropriate emergency protocol and that hyaluronidase is present in the clinical setting at the time of injection.

Vascular compromise is the most serious acute complication of filler injection and can result in tissue necrosis or, in rare cases, blindness if embolic material reaches the ophthalmic circulation. Published protocols (including those from Save Face and the JCCP emergency management guidance) recommend immediate high-dose hyaluronidase at the first sign of vascular compromise, without waiting for confirmatory imaging. Practitioners should review the current JCCP vascular occlusion protocol and ensure team members are briefed.

Documentation, Consent, and the JCCP Register

Since the commencement of the CQC licensing regime in England and the parallel JCCP registration framework, documentation standards for injectable aesthetic procedures have become substantially more detailed. A compliant consultation record should include: a full medical history including all medications and supplements, photographic record with patient consent, a discussion of realistic outcomes and material risks including vascular occlusion, anaphylaxis, and filler-associated nodules, written consent, and a post-procedure care plan with emergency contact information.

The JCCP's published Standards Framework (available via jccp.org.uk) provides a practical reference for the required scope of documentation. Practitioners not yet listed on the JCCP register are strongly encouraged to engage with the registration pathway to avoid referral risk and reputational exposure as the regulatory environment continues to tighten.

See the full range of practitioner supplies, including consultation and consent documentation packs, at /collections/all-products.

Frequently Asked Questions

What does MHRA Class III classification mean for my filler purchasing decisions?

Class III is the highest risk tier for medical devices under the UK Medical Devices Regulations 2002. It means the product has undergone conformity assessment by an approved body, holds a UK CA mark or is on an MHRA-recognised transitional register, and the manufacturer is subject to ongoing post-market surveillance obligations. As a practitioner, you should ask your supplier for device registration evidence before placing any order. Longeva Aesthetics can provide this documentation for every product line we stock.

How does G-prime influence which filler I should choose for the mid-face versus the lips?

G-prime (elastic modulus) is a measure of gel stiffness. For the mid-face, where you need a product to resist the compressive forces of overlying soft tissue and provide structural lift, a higher G-prime product is generally indicated. For the lips, where the tissue is mobile and natural movement is essential to a good aesthetic result, a lower G-prime, more flexible formulation integrates better and avoids the palpable firmness that can occur with overly stiff products. Most manufacturer portfolios stratify their products by G-prime, and independent rheological data are available in the peer-reviewed literature.

Are all HA dermal fillers reversible with hyaluronidase?

Cross-linked HA fillers are enzymatically degradable by hyaluronidase, and this remains one of the key safety advantages of HA-based products over permanent or semi-permanent fillers. However, the speed and completeness of dissolution depends on the degree of cross-linking, the volume injected, and the time since injection. Highly cross-linked products (high G-prime) typically require higher doses of hyaluronidase for complete dissolution. In the context of vascular occlusion, the JCCP emergency protocol recommends immediate high-dose administration; practitioners should not hesitate pending dose calculation if ischaemic signs are present.

What is the correct storage temperature range for HA dermal fillers?

The vast majority of HA filler SPCs specify storage between 2 and 25 degrees Celsius, in a clean, dry location away from direct sunlight and sources of heat. Products must never be frozen, as ice crystal formation can disrupt the cross-linked gel matrix and compromise product integrity and sterility. On arrival from a supplier, verify that packaging is intact and that the product has been shipped under appropriate temperature-controlled conditions. Reject any delivery where cold-chain documentation is absent or where packaging integrity is in question.

Do I need to be on the JCCP register to purchase dermal fillers from Longeva Aesthetics?

Longeva Aesthetics is a B2B-only supplier, and all purchases require proof of a relevant clinical qualification or registration. While the JCCP register is a widely referenced standard and is strongly recommended by NHS England and the major professional bodies, the minimum requirement for purchase is evidence of an appropriate clinical qualification and, for practitioners in England, a valid CQC licence for the procedure type. We review credentials at account registration, and our compliance team may request updated documentation periodically in line with evolving regulatory requirements.